Why Is Celcuity (CELC) Stock Down -5.29% Today?
Key Takeaways
- Shares of CELC fell 5.29% to $57.11 in Friday's session, extending a multi-week slide from its post-approval highs.
- The decline followed a wave of analyst downgrades, including a "strong sell" rating from Zacks Research, which weighed on sentiment.
- The move reflects lingering post-approval disappointment around the commercialization of REVTORPYK (gedatolisib) and its tolerability profile.
- The stock continues to trade below its 50-day and 200-day moving averages, reinforcing a technical downtrend.
- Traders are watching upcoming quarterly results and early launch metrics for the company's first commercial product.
Opening Summary
CELC, or Celcuity Inc., is a Minneapolis-based biotechnology company that recently transitioned from clinical-stage to commercial-stage with the U.S. Food and Drug Administration approval of its lead drug candidate gedatolisib, branded REVTORPYK, for certain patients with advanced HR+/HER2- breast cancer. On Friday, shares dropped 5.29%, falling $3.19 to $57.11 from a prior close of $60.30, as bearish analyst commentary and fading post-launch momentum pressured the stock.
Analyst Downgrades Fuel the Selloff
The most immediate catalyst behind the session's decline was a fresh round of bearish ratings. Zacks Research lowered its view on CELC from "hold" to "strong sell," while Wall Street Zen also carried a "strong sell" rating. Although the broader analyst consensus remains a "Moderate Buy" with an average price target well above current levels, the downgrades underscored growing near-term caution and prompted selling pressure in a stock that had already been trending lower.
Post-Approval Hangover and Launch Concerns
The downgrades landed against a backdrop of persistent disappointment since the company's landmark FDA approval in July. While REVTORPYK's approval marked Celcuity's first marketed product, the stock has sold off sharply in the months since. Management pushed the commercial launch to late in the third quarter to secure supply, and the drug's label carried tolerability baggage — in combination studies, a large share of patients experienced mouth inflammation, with some discontinuing treatment. The resulting expectations reset has kept the stock under pressure even as the product reached the U.S. market, with CELC trading near the lower end of its 12-month range.
Technical Weakness and Market Context
The decline also reflects a broader technical breakdown. CELC is trading well below its 50-day and 200-day simple moving averages, a sign that near- and longer-term momentum remain negative. The stock has carved a pattern of lower highs and lower lows since mid-September, and Friday's move pushed it deeper into oversold territory. Trading volume has remained elevated relative to recent sessions, consistent with sustained distribution rather than a single isolated event. The weakness in CELC reflects company-specific concerns more than broad biotech-sector weakness, as investors continue to de-rate the name despite its newly commercial status.
What Comes Next for CELC
Looking ahead, investors will focus on early REVTORPYK launch metrics and the company's next quarterly report, which should offer the first meaningful read on how the drug is ramping commercially after a delayed start. Celcuity has also indicated plans to pursue label expansion for the roughly 40% of patients whose tumors carry a PIK3CA mutation, a move that could meaningfully expand its addressable market. Key risks include the pace of commercial uptake, the drug's tolerability profile, and the company's significant cash burn and convertible-debt load as it builds out its commercial infrastructure. For now, the stock remains caught between a Street consensus that sees substantial upside and a market that is demanding clearer evidence of a successful launch.
Trending AI Robots
For traders seeking a more systematic approach to volatile names like CELC, Tickeron's Trending AI Robots page offers a curated look at the platform's top-performing automated strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches aligned with their own goals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CELC in -9.04% downward trend, declining for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CELC declined for three days, in 238 of 280 cases, the price declined further within the following month. The odds of a continued downward trend are 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CELC turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 36 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
The Aroon Indicator for CELC entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELC advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CELC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (84.746) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company develops novel diagnostic tests
Industry Biotechnology
Advertisement